

Canadian Bioinformatics Workshops

www.bioinformatics.ca

This page is available in the following languages:

Afrikaans български Català Dansk Deutsch Еλληνικά English (CA) English (GB) English (US) Esperanto Castellano (AR) Español (CL) Castellano (CO) Español (Ecuador) Castellano (MX) Castellano (PE) Euskara Suomeksi français français (CA) Galego איביי hrvatski Magyar Italiano 日本語 한국어 Macedonian Melayu Nederlands Norsk Sesotho sa Leboa polski Português română slovenski jezik српски srpski (lalinica) Sotho svenska 中文 季語 (台灣) isiZulu



Attribution-Share Alike 2.5 Canada

You are free:



to Share - to copy, distribute and transmit the work



to Remix - to adapt the work



Under the following conditions:



Attribution. You must attribute the work in the manner specified by the author or licensor (but not in any way that suggests that they endorse you or your use of the work).



Share Alike. If you alter, transform, or build upon this work, you may distribute the resulting work only under the same or similar licence to this one.

- . For any reuse or distribution, you must make clear to others the licence terms of this work.
- · Any of the above conditions can be waived if you get permission from the copyright holder.
- The author's moral rights are retained in this licence.

Disclaime

Your fair dealing and other rights are in no way affected by the above.


This is a human-readable summary of the Legal Code (the full licence) available in the following languages:


English French

Module 1 Introduction to Pathway and Network Analysis of Gene Lists



Gary Bader Pathway and Network Analysis of –omics Data





ΓORONTO


July 27-29, 2020



http://baderlab.org


Interpreting gene lists

- My cool new screen worked and produced 1000 hits! ...Now what?
- Genome-Scale Analysis (Omics)
 - Genomics, Proteomics
- Tell me what's interesting about these genes




Interpreting gene lists

- My cool new screen worked and produced 1000 hits! ...Now what?
- Genome-Scale Analysis (Omics)
 - Genomics, Proteomics
- Tell me what's interesting about these genes
 - Are they enriched in known pathways, complexes, functions



Pathway and network analysis

Save time compared to traditional approach



Pathway and network analysis

- Helps gain mechanistic insight into 'omics data
 - Identifying a master regulator, drug targets, characterizing pathways active in a sample
- Any type of analysis that involves pathway or network information
- Most commonly applied to help interpret lists of genes
- Most popular type is pathway enrichment analysis, but many others are useful

Autism spectrum disorder (ASD)


- Genetics
 - highly heritable
 - monozygotic twin concordance 60-90%
 - dizygotic twin concordance 0-10%
 (depending on the stringency of diagnosis)
 - known genetics:
 - 5-15% rare single-gene disorders and chromosomal rearrangements
 - de-novo CNV previously reported in 5-10% of ASD cases
 - GWA (Genome-wide Association Studies) have been able to explain only a small amount of heritability

Pinto et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010 Jun 9.


Rare copy number variants in ASD

- Rare Copy Number Variation screening (Del, Dup)
 - 889 Case and 1146 Ctrl (European Ancestry)
 - Illumina Infinium 1M-single SNP
 - high quality rare CNV (90% PCR validation)
 - identification by three algorithms required for detection
 - QuantiSNP, iPattern, PennCNV
 - frequency < 1%, length > 30 kb
- Results
 - average CNV size: 182.7 kb, median CNVs per individual: 2
 - > 5.7% ASD individuals carry at least one de-novo CNV
 - Top ~10 genes in CNVs associated to ASD

Pathways enriched in autism spectrum




Zoom of CNS-Development



Ependymoma pathway analysis

- Ependymoma brain cancer most common and morbid location for childhood is the posterior fossa (PF = brainstem + cerebellum)
- Two classes: PFA young, dismal prognosis, PFB older, excellent prognosis. Determined by gene expression clustering.
- Exome sequencing (42 samples), WGS (5 samples) showed almost no mutations, however methylation arrays showed clear clustering into PFA and PFB (79 samples)
- PFA more transcriptionally silenced by CpG methylation


Witt et al., Cancer Cell 2011 Nature. 2014 Feb 27;506(7489):445-50 Steve Mack, Michael Taylor, Scott Zuyderduyn



polycomb repressor complex 2 – inhibited by SAHA, DZNep, GSK343 – killed PFA cells No known treatment, so now going to clinical trial

9 yo with metastatic PF ependymoma to lung treated with azacytidine









2 months 3 months 3 cycles Vidaza

Effect lasted 15 months

Molecular classification of ependymal tumors



ScRNA-seq of 5 healthy livers reveals 20 cell types



8444 single cells from five human liver samples




Public data, contributed to Human Cell Atlas (https://www.humancellatlas.org)

shiny.baderlab.org/HumanLiverAtlas/

MacParland et al., Oct.22.2018, Nature Communications

Pathway analysis identifies the division of labour among hepatocyte populations



Pathway analysis by GSVA

Periportal Pericentral

L9

Mouse Hepatocyte Layers (Halpern et al., 2017)

Example: Genome Wide Association Study (GWAS)

Genotypes for 10 cases and 10 controls – ideal situation

			Cases	•		Controls					
SNP	1	2	3	4	5	6	7	8	9	10	
Α	1	1	1	1	1	0	0	0	0	0	
В	0	0	0	0	0	0	0	0	0	0	
С	0	0	0	0	0	0	0	0	0	0	
D	0	0	0	0	0	1	1	1	1	1	
E	0	0	0	0	0	0	0	0	0	0	
F	0	0	0	0	0	0	0	0	0	0	

Mutation A is perfectly associated with cases (5/5) Mutation D is perfectly associated with controls (5/5)

Example: Genome Wide Association Study (GWAS)

More realistic situation:

	Cases					Controls					
SNP	1	2	3	4	5	6	7	8	9	10	
Α	1	0	0	0	0	0	0	0	0	1	
В	0	1	0	0	0	0	0	0	0	0	
С	0	0	1	0	0	0	0	0	1	0	
D	0	0	0	1	0	0	0	1	0	0	
E	0	0	0	0	1	0	1	0	0	0	
F	0	0	0	0	0	1	0	0	0	0	

No mutation is associated with cases or controls

Example: Genome Wide Association Study (GWAS)

Pathway analysis view: SNPs A-F are part of one pathway

			Cases	5		Controls					
Pathway	1	2	3	4	5	6	7	8	9	10	
Apoptosis	1	1	1	1	1	0	0	0	0	0	

- Mutations in 'apoptosis' pathway are perfectly associated with cases (5/5)
- Increased statistical power via aggregating counts and reducing multiple testing
- Generating mechanistic hypotheses (i.e. apoptosis is related to the case phenotype)

Pathway analysis benefits

What do 1000 differentially expressed genes have in common?





Benefits of pathway analysis

vs. transcripts, proteins, SNPs...

- Easier to interpret
 - Familiar concepts e.g. cell cycle
- Identifies possible causal mechanisms
- Predicts new roles for genes
- Improves statistical power
 - Fewer tests, aggregates data from multiple genes into one pathway
- More reproducible
 - E.g. gene expression signatures
- Facilitates integration of multiple data types

Pathway analysis workflow overview






Workshop outline

- Computational analysis methods we will cover
 - Day 1: Pathway enrichment analysis: summarize and compare
 - Day 2: Network analysis: predict gene function, find new pathway members, identify functional modules (new pathways)
 - Day 3: Regulatory network analysis: find and analyze controllers

We are on a Coffee Break & Networking Session



Workshop Sponsors:





